Osimertinib prolongs PFS and OS in selected NSCLC patients [4, 24], irreversibly inhibiting both EGFR sensitizing mutations and EGFR exon 20 T790M mutation [25]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.